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Developmental neurotoxicity is any effect of a
toxicant on the developing nervous system
before or after birth that interferes with normal
nervous system structure or function. Exposure
to xenobiotics during development can cause
adverse structural, functional, neurochemical,
or behavioral effects. Studies conducted on
laboratory animals to detect or characterize
developmental neurotoxicity typically focus on
behavioral and pathologic effects and rarely
involve consideration of pharmacokinetic or
pharmacodynamic processes. These studies
have been used as the basis for human health
risk assessment for regulatory purposes for
many years (1–3), and are discussed in com-
panion articles in this journal (4,5). The value
of developmental neurotoxicity studies con-
ducted in laboratory animals can be increased
by consideration of pharmacokinetic processes
(e.g., absorption, distribution, metabolism,
and elimination processes) and pharmaco-
dynamic effects (e.g., physiologic, biochemical,
and molecular effects) of a chemical on the
organism in study design and interpretation.
We outline pharmacokinetic and pharmaco-
dynamic data that can be used to improve
risk assessment of developmental neuro-
toxicants. Pharmacologic data can verify or
characterize exposure, refine the dose–
response curve, determine chemical delivery
to a target site, and identify effects on physi-
ologic systems resulting from exposure to the
study compound. These pharmacokinetic
and pharmacodynamic data collected from
animals may be used to replace or modify
default assumptions related to dose–response
assessment and to extrapolate from animal
data to human scenarios, thus reducing
uncertainty in risk assessment (6). Here we
focus on studies conducted in the rat, the test
species most commonly used in developmen-
tal neurotoxicity studies, although we refer to
other species to illustrate pharmacologic
factors that should be considered to improve
experimental design of developmental neuro-
toxicity studies.
For several reasons, pharmacokinetic and
pharmacodynamic processes often are more
complicated in the developing nervous system
than in the adult. For example, dynamic
physiologic changes occur in the maternal–
placental–fetal unit during pregnancy and in
the offspring during postnatal development.
Brain growth is rapid before and after birth,
and access of chemicals to the brain may
change as the blood–brain barrier (BBB)
develops and matures. Exposure to the con-
ceptus often depends on transfer of the toxi-
cant from the dam to the developing animal
via the circulation in utero and the milk dur-
ing lactation. Thus, exposure to the develop-
ing nervous system is a function of the dose
administered to the dam and the pharmaco-
kinetics of the compound in the maternal,
placental, and embryo/fetal (or neonatal) cir-
culations. Changes in either maternal or off-
spring pharmacokinetics could therefore
affect the extent to which the developing ner-
vous system is exposed. In addition, the
intrinsic vulnerability of the nervous system
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to toxic agents varies with developmental
stage at which exposure occurs, i.e., there are
critical periods, both pre- and postnatally, for
disruption of structural and functional ner-
vous system development [(7); for review see
Rice and Barone (8) and Adams et al. (9)].
There may be a heightened sensitivity of the
immature nervous system to toxic insult as a
result of various developmental processes such
as cell formation, migration, development of
neurites, and establishment of intercellular
connections. There may also be greater expo-
sure of the immature (vs. mature) nervous
system to toxic chemicals. The pharmaco-
kinetics and toxic effects of a test compound
should therefore be evaluated during the rele-
vant period of development.
Pharmacokinetic and pharmacodynamic
data might be used to address questions such
as whether gestational exposure to the devel-
oping nervous system occurs in utero, and
whether the compound is transferred to the
milk, creating lactational exposure. If expo-
sure is confirmed based on pharmacokinetic
data or if neurotoxicity is observed in the
developing animal, the next step may be dose
characterization in the dam and offspring.
To characterize exposure and dose response
for study design or interpretation, a
pharmacokinetic profile in the dam and
embryo/fetus or pup can be generated based
on available data or through pharmaco-
kinetic modeling. The ultimate goal in risk
assessment is to describe the entire exposure,
target tissue dose, and toxic response contin-
uum for more accurate extrapolation to
humans (Figure 1).
Factors That Modify in Utero
Exposure of the Developing
Nervous System
Factors that determine whether prenatal
exposure to a xenobiotic will cause develop-
mental toxicity include the pharmacody-
namic action of the xenobiotic on the
conceptus, the prenatal developmental stage
at which exposure occurs, and the concentra-
tion of the active form of the xenobiotic
reaching the conceptus in utero. 
Chemicals may produce developmental
neurotoxicity directly by acting on the fetus
or indirectly by inducing maternal effects.
Most indirect effects result from altered deliv-
ery of oxygen, glucose, amino acids, specific
coenzymes, and other substrates to the fetus.
Indirect effects can arise from placental insuf-
ﬁciency, by direct effects on maternal glucose
regulation (e.g., by hypoglycemic agents), or
by alterations in maternal ventilatory control
(e.g., opiate-induced hyperventilation or
hypoventilation). Some xenobiotics are likely
to act through more than one mechanism.
For example, ethanol has speciﬁc teratogenic
effects in both the embryonic and fetal period
but may also alter maternal nutrition and
disturb fetal acid–base balance (10).
The nature and incidence of developmental
effects of chemicals depend on the develop-
mental stage insulted (11). In general,
exposures to certain chemicals during pre-
differentiation early in gestation do not pro-
duce congenital malformations but instead
lead to embryonic death or abortion (12).
Similarly, the embryo is highly susceptible to
teratogenic insult during organogenesis
because organ development is continual
within this period (11). After organogenesis,
the developing nervous system can remain
susceptible to chemical insult (8,13).
Although major brain structures are largely
completed during organogenesis, neuronal
migration occurs and neuronal connections
continue to be formed through early neo-
natal life; thus, brain organization is an
important consideration during the fetal and
postnatal periods (14).
The concentration of the active form of a
xenobiotic reaching the conceptus in utero is
another important determinant of effect and
is influenced by maternal and fetal metabo-
lism. Numerous xenobiotics are known to
exert their toxicities only after metabolic acti-
vation by various enzymes within the body
[reviewed by Juchau (15)]. Biotransformation
may vary among species or individuals based
on genetic or physiologic variables such as
pregnancy, disease, or chronic drug therapy.
Therefore, establishing whether metabolism is
qualitatively and quantitatively similar among
different species is important when making
interspecies extrapolations. For example, dif-
fering susceptibilities of various inbred mouse
strains, and possibly human individuals, to
the developmental effects of phenytoin may
involve genetically determined differences in
phenytoin biotransformation (16,17), and
different sensitivities to retinoid developmen-
tal toxicity among species can be attributed
partly to differences in metabolism (18).
The activity of hepatic microsomal drug-
metabolizing enzymes increases during human
pregnancy, leading to an increase in hepatic
clearance of certain drugs and chemicals (19).
Conversely, the hepatic microsomal metabo-
lizing enzyme activity in rats decreases during
gestation to approximately 50% of control
levels [for review see Oesterheld (20)]; how-
ever, the total metabolic capacity of the rat
liver may remain constant or can increase dur-
ing pregnancy because liver hypertrophy leads
to increased (~40%) liver weights in pregnant
rats (21). The human fetus possesses a well-
developed complex of drug-metabolizing
enzymes, albeit less active than those of the
adult, whereas fetuses of common laboratory
animals may be deﬁcient in drug-metabolizing
activity (22–28). This difference between
human and rat fetus enzyme activity may be a
disadvantage of the rat model. Even though
levels of hepatic and extrahepatic cytochrome
P450 enzymes are lower in the rat fetus than
in the dam, some investigators have hypothe-
sized that these levels may be sufﬁcient to cat-
alyze deleterious biotransformation reactions
(29). Fetal tissues and placenta are deﬁcient in
A-esterases and carboxylesterase (30), two
enzymes that may limit detoxification of
organophosphate and pyrethroid insecticides
in the fetus.
Plasma protein binding is another impor-
tant determinant of xenobiotic disposition
and action. Significant changes in plasma
protein composition can occur during preg-
nancy (31,32). Both albumin and α -1 acid
glycoprotein fractions are reduced during
pregnancy, and the pharmacokinetics of
highly protein-bound acidic and basic drugs
are affected. Plasma protein levels of the
developing offspring undergo changes during
development (33) that may lead to increased
levels of free (i.e., protein-unbound) drugs.
Differences in the degree of protein binding
between maternal and umbilical cord plasma
have been demonstrated. In some cases these
differences in plasma protein binding may be
sufﬁcient to account for a difference in total
drug concentration between maternal and
fetal plasma (32). Xenobiotic binding to fetal
or neonatal plasma proteins may displace
endogenous substrates that are normally
bound to these proteins. For example, the
competitive displacement of bilirubin from
Figure 1. Overview of pharmacokinetic processes that occur during nervous system development. AUC represents
the area under the concentration–time curve.
Exposure Target tissue concentration of
parent chemical or metabolite
Receptor binding and other
biochemical effects
Toxicologic response Altered functional status Cellular responses
Peak concentration AUC
Pharmacokinetic issues:
In utero exposure: placental transfer, crossing of fetal BBB, maternal toxicity, periods of susceptibility
Postnatal exposure: lactational transfer, crossing of neonatal BBB, time of dosing, dose–route
concentrations (inhalation, dermal, oral)
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other drugs is one cause of clinical jaundice in
infants (31,34,35). 
Most foreign chemicals that gain access to
the conceptus after maternal exposure do so
through placental transfer (36,37), although
some chemical exposure can occur before
implantation. Factors that inﬂuence the rate
of chemical transfer across the placenta are the
thickness and surface area of the placental
membrane, placental blood flow, molecular
size and lipid solubility of the chemical,
plasma protein binding of the chemical, and
respective pHs of the maternal and fetal circu-
lation [for review see Pratt (38)]. Most xeno-
biotics cross the placenta by passive diffusion
and do so in accordance with their solubility
characteristics (39). Low molecular-weight,
lipophilic chemicals (e.g., many pesticides) are
fully capable of crossing the placental mem-
branes, and their rate of transfer is limited by
placental blood ﬂow. The placental transfer of
anticholinesterase pesticides provides one well-
documented example of this process (40–45).
In contrast, high molecular-weight (> 1,000
Da) or ionized, hydrophilic compounds cross
the placenta very poorly or not at all,
depending on their molecular radii and the
presence or absence of charged functional
groups. They also cross the BBB at a rate
slower than the rate of delivery by the blood-
stream. This process is called membrane-
limited transfer, and the constitution of the
membranes determines the rate of transfer.
There are marked interspecies differences
in types of placenta, orientation of exchang-
ing vessels, and number of exchanging layers
(46). Although these differences do not play a
dominant role in the placental transfer of
most drugs and chemicals, large species differ-
ences have been shown for placental perme-
ability of hydrophilic molecules. For example,
in sheep there is no signiﬁcant diffusional ﬂux
for hydrophilic compounds with a molecular
weight up to 400 Da. In the guinea pig, how-
ever, there is no restriction in diffusion for
molecules with weights up to 5,000 Da. The
permeability of human placenta is consider-
ably higher than sheep placenta and is more
comparable to guinea pig placenta (47). 
The observed species differences in
placental transfer of hydrophilic xenobiotics
are caused predominantly by structural differ-
ences among placenta (Table 1). Both the
human and rat placentae are hemochorial—
that is, the fetal chorionic villi bathe in lacu-
nae of maternal blood. In the human
placenta, the villous capillary is separated
from maternal blood by three layers of cells
(48). The layers of the rodent chorionic villus
are similar; however, they have an additional
layer of cytotrophoblasts (48). The villous
nature of the human placenta produces a
haphazard arrangement that promotes a
cross-current exchange between the maternal
and fetal circulations. In rodents the ﬂow sys-
tem is mainly countercurrent, producing
more efﬁcient exchange. The high permeabil-
ity of the human and guinea pig placenta,
compared with the sheep placenta, may occur
because the human and guinea pig have a
thin hemochorial type of placenta, whereas
the sheep has a epitheliochorial placenta in
which more tissue layers separate the mater-
nal and fetal bloodstreams. In the human
hemochorial placenta, the trophoblast and
the endothelium are responsible for the diffu-
sional resistance to hydrophilic compounds.
The trophoblastic components determine the
overall diffusion barrier, and intercellular
spaces in the endothelium restrict the diffu-
sion of larger molecules. Trophoblasts within
the placenta also express P-glycoprotein,
which may protect the fetus from xenobiotic
exposure (49).
Besides differences in placental anatomy,
both human and rodent placentae undergo
considerable changes throughout gestation as
the normal developmental process proceeds
(50). For example, enhanced blood ﬂow to the
placenta, increased fetal vasculature size, and
proliferation of maternal vascular microvilli all
contribute to increased efﬁciency of transpla-
cental transport in guinea pigs during late ges-
tation (51). The enhanced placental transfer of
13-cis-retinoic acid observed in rodents during
later stages of gestation has been attributed to
such maturational changes (52).
Several enzymes that can metabolically
activate or deactivate certain compounds have
been found in the human placenta as well as
in the embryo and fetus, although in amounts
lower than those found in the mother (37,53).
As discussed by Hakkola et al. (37), relatively
little is known about the role of placental
metabolism in modulating prenatal develop-
mental toxicity, but the levels of these metab-
olizing enzymes can change throughout
gestation. Although the overall contribution
of these enzymes to maternal pharmacokinet-
ics is probably negligible, intrauterine activa-
tion of chemicals might contribute to toxic
outcomes in the embryo or fetus (54,37).
Factors That Modify Postnatal
Exposure of the Developing
Nervous System
Once parturition occurs, exposure of
offspring to a test chemical and or its
metabolites generally occurs through the
milk. Although some preformed, endoge-
nous, systemic substances are found in milk
(55), a selective blood–milk barrier exists for
the mammary ducts of most species studied.
Various factors affect the entry of com-
pounds into breast milk, including molecular
size, lipophilicity, and pH [for review see
Wilson (56) and Wilson et al. (57)]. The
transfer of drugs, chemicals, and micromole-
cular nutrients from blood to the milk occurs
via mechanisms similar to transport mecha-
nisms of other membranes. Such mecha-
nisms include diffusion through water-filled
pores, diffusion of lipid-soluble compounds
through lipid membranes, and active, or car-
rier-mediated, transport. Passive diffusion is
affected mainly by the chemical or drug dis-
position in lactating mothers, the physico-
chemical properties of the molecule, and the
protein and lipid content of breast milk. In
general, lipophilic chemicals penetrate mem-
brane barriers easily and are preferentially
concentrated in the milk fat globules, which
can lead to a high ratio of chemical in milk
compared to plasma. Because lipophilic com-
pounds partition into fat, the fat content of
breast milk is a major determinant of the
chemical level in whole milk. The concentra-
tion of fat and other nutrients in the milk
varies among species. Mature human milk
contains approximately 3–5% fat, 0.8–0.9%
protein, 6.9–7.2% carbohydrate calculated as
lactose, and 0.2% mineral constituents
expressed as ash (58). The concentration of
protein (8–12%), fat (11–15%), iron, and
copper in rat milk is higher than that found in
human breast milk (59). Within each species,
fat and other nutrient concentrations vary
throughout lactation period postprandially
and diurnally (59).
The pKa of a weak acid or base is a
primary determinant of its ability to enter
Pharmacokinetics in developmental neurotoxicology
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Table 1. Placental morphology and classiﬁcation in humans and common laboratory animals.
Tissue layers
Placental type mb mce mct me is tr fct fce fb Species
Epitheliochorial + + + + + + Sheep, pig
Endotheliochorial + – – + + + Dog, cat
Hemochorial
mono – – – + + + Human, 
guinea pig
di – – – ++ + + Rabbit
tri – – – +++ + + Rat, mouse
Abbreviations: +, number of cell layers; fb, fetal blood; fce, fetal capillary endothelium; fct, fetal connective tissue; is, intervillous
space; mb, maternal blood; mce, maternal capillary endothelium; mct, maternal connective tissue; me, maternal epithelium; tr,
trophoblast. Maternal blood is represented by a shaded column, as are intervillous space and fetal blood. The placentas of all species
listed contain these layers. Columns between these layers represent cell layers (if any) that separate mb, is, and fb. Data modiﬁed
from Page (181).
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breast milk. The pH of breast milk is generally
6.6–6.8 in the human and therefore more
acidic than plasma. Thus, basic compounds
are often trapped in the milk and reach higher
levels, whereas acidic compounds are inhibited
from entry, producing lower levels. Breast
milk can be considered a compartment with
bidirectional transfer rather than a reservoir
into which drugs accumulate. The amount of
many pharmaceutical agents or drugs excreted
in milk is signiﬁcantly lower than the mater-
nal dose; however, there are a number of
exceptions [for review see Berlin (60) and
Berglund et al. (61)]. Conversely, the amount
of many chemicals or environmental agents in
the offspring can often be higher than in the
mother. For example, highly lipid-soluble
chemicals (e.g., DDT and other organochlo-
rine insecticides) may remain in body fat for
very long periods and represent a hazard to
the nursing infant (62,63). Metals chemically
similar to calcium, such as lead, may accumu-
late in breast milk. These interactions could
deliver signiﬁcantly higher amounts of chemi-
cal to the nursing offspring than would be
estimated based upon maternal levels.
Although some data describe milk levels of
pharmaceutical agents, few data characterize
human milk levels of environmental chemi-
cals. Few studies reporting both milk and
infant plasma levels are found in the toxico-
logic literature, and the validity of assump-
tions in predictive models for drugs has not
been evaluated. Data are available from exper-
imental animal studies, human epidemiologic
studies, and case reports on the lactational
transfer and uptake in the neonate of inor-
ganic mercury, methylmercury (64), lead (65),
cadmium (66), polychlorinated biphenyls
(PCBs) (67,68), tetrachloroethylene (69),
radioiodine (70,71), hexachlorobenzene (72),
and other organochlorine chemicals (73). 
The concentration of a chemical in milk
depends on the rate of transfer across the
epithelium and the half-life of the substance
in the plasma. Chemicals with a short plasma
half-life may not have time to equilibrate
across the mammary epithelium, so milk con-
centrations may be low compared with
plasma concentrations. The key starting point
for estimating the amount of compound in
the milk is the free concentration of drug or
chemical in the maternal plasma. Total
plasma concentration is used often as a surro-
gate for this calculation. Peak plasma concen-
tration following single or repeated exposure
is a function of the dose and dose rate, route
of exposure, bioavailability, volume distribu-
tion, and amount of drug eliminated during
the assimilation phase. The decline in plasma
concentration after the peak is determined
largely by the elimination half-life. These
factors also determine the concentrations of
drugs or chemicals achieved in the suckling
infant, with the dose rate being the amount
ingested over time in the mother’s milk.
However, the offspring blood levels of chemi-
cal also depend on the degree of absorption in
the gastrointestinal tract, as well as distribu-
tion, metabolism, and excretion. The milk-
to-plasma (M:P) ratio, which compares milk
drug concentration with maternal plasma
drug concentration, serves as an index of the
extent of drug excretion in the milk. The
impact of these various determinants has been
quantiﬁed, and pharmacokinetic models have
been established for predicting the behavior
of unstudied chemicals (57,74–77).
These principles have been used successfully
to describe M:P partitioning of many chemi-
cals. However, in vivo studies in a variety of
species have identified some drugs that are
found in milk at higher-than-predicted con-
centrations. Drugs for which this is true
include aminopyrine (78), N4-acetylated
p-aminohippuric acid (79), N4-acetylated
sulphanilamide (80), acyclovir (81), cimeti-
dine (82–85), and nitrofurantoin (86). The
unpredictable M:P ratios observed for these
compounds may be due to an active transport
mechanism.
An additional concern that should be
considered in lactational exposure studies is
the potential for the xenobiotic to alter milk
secretion and composition. Such interference
can occur in mammary development, secre-
tion by mammary alveolar cells, hormonal
support for lactation, or nutrient transport
[for review see Neville and Walsh (87)].
Methods Used to Conﬁrm
Exposure of the Developing
Nervous System
Several factors should be considered when
designing studies to assess whether placental
transfer of a chemical might occur. Single
time-point measurements of either maternal
or fetal chemical concentrations are difficult
to interpret in developmental neurotoxicity
studies for various reasons. First, some xeno-
biotics may be transported more readily
across the placenta during late gestation than
during early gestation. Second, placental
transfer may vary over time, depending on
the dosing paradigm used (i.e., bolus injec-
tion vs. dietary exposure). In addition, it is
difficult to predict whether a bolus dose or
continuous infusion of a chemical given to
the dam will lead to a higher concentration
within the embryo/fetus; either may produce
a higher exposure, depending on the sub-
stance administered. Substances that are elim-
inated rapidly from the maternal circulation
tend to lead to fetal plasma concentrations
that are only a fraction of the maternal peak
concentration. 
Current research techniques to measure
placental transfer include the use of the
chronically cannulated sheep, rabbit, or
monkey, the isolated perfused human pla-
centa or placental lobule, and the small-ani-
mal placenta (rabbit, guinea pig, and even
rat) perfused in situ to determine transfer
rates for chemicals (88). Concentration gradi-
ents across the sheep placenta are often larger
than in primates, especially for less lipid-solu-
ble chemicals (89). The large litter size of rab-
bits allows individual fetuses to be removed in
sequence to measure chemical concentrations
in both plasma and tissue (90,91). Small lab-
oratory animals may be used to characterize
distribution of the toxicant, with either
autoradiography (92) or extraction and chem-
ical assay (91) used to detect the toxicant. 
The concentration of xenobiotic in the
fetus may be estimated from the placental
transfer rate and the rate of direct elimination
by the fetus using the concentration-time
course of the chemical in the mother.
Depending on the particular xenobiotic,
pharmacokinetic end points of interest can
include comparisons of peak (or trough) fetal
and maternal concentrations, area under the
concentration-time curve (AUC), and mean
steady-state concentrations in the fetus and
dam expressed as a fetal-to-maternal ratio. 
A transplacental binding gradient may
account partly for the differences in placental
transfer and teratogenic potency between
all-trans and 13-cis-retinoic acid in the mouse
(93). A pH gradient across the placenta also
appears to play a role in the extent of placental
transfer of some substances. The embryonic
compartment is alkaline relative to maternal
plasma during early rodent organogenesis,
and several teratogenic weak acids can accu-
mulate in the embryo during this period, pre-
sumably by ion trapping (94). This concept
has been formalized in a physiologically based
pharmacokinetic (PBPK) model (95). 
Experimental animal studies evaluating
placental (and lactational) transfer often rely
on the use of high-purity radiolabeled chemi-
cals to determine xenobiotic distribution pat-
terns in the dam and fetus or neonate. The
use of radiolabeled chemicals also facilitates
mass balance determinations. Measurement
of radiochemicals often relies on whole-body
autoradiography techniques using small num-
bers of animals. Because individual radiola-
beled isotopes are followed, interpretation of
these studies requires some knowledge of the
metabolism to ensure that the radiolabel
remains with the metabolite of interest.
Studies examining the transfer and distribu-
tion of nonradiolabeled chemicals require the
development of sensitive analytic methodolo-
gies to evaluate the parent compound and its
metabolites. 
Exposure to the developing animal in utero
can be conﬁrmed using analytic techniques to
measure the parent compound or active
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metabolite in plasma, blood, or amniotic ﬂuid.
Evidence of exposure in nursing neonates can
be demonstrated by determining the concen-
tration of the test substance and its important
metabolites in pup blood or tissue during the
lactation period or by measuring chemical-
specific biomarkers of exposure or effect in
pups (e.g., cholinesterase inhibition or car-
boxylesterase inhibition). The measurement of
toxicant concentrations in milk is often used as
a surrogate to confirm neonatal exposure.
Changes in the magnitude of exposure over
time can be estimated by sampling either the
maternal milk or stomach contents of the pups
at several time points during the lactation
period. Each of these sampling procedures is
hindered by the preference for a terminal sacri-
fice of the experimental animal for adequate
sampling. An alternative approach is to employ
cross-fostering in the experimental design to
distinguish between body burden of a drug or
chemical resulting from gestational or lacta-
tional routes of exposure. Exposure in the
developing animal can be conﬁrmed by meas-
uring a biomarker of exposure or effect rather
than the actual toxicant.
Characterization of Exposure
In studies where only maternal animals are
treated and there is little or no opportunity
for other types of postnatal exposure (such as
in a gavage study), exposure in pups is medi-
ated by the presence of the test substance or
its metabolites in milk, the presence of nor-
mal lactation function and behavior on the
part of both dam and pups, and the volume
of milk consumed by the pups. In this type of
treatment scenario the amount of test sub-
stance delivered to the pups via the milk does
not remain constant because levels in milk
may change over time (96), and milk intake
decreases in late lactation. 
Some other types of exposure in the pups
can occur in early or late lactation, depending
on the study design and route of administra-
tion. For instance, pups could be exposed to
the test substance by ingesting the material
from the maternal skin if it has been dermally
applied to the dams (or if there is residual
material on dams dosed by inhalation in a
whole-body chamber), by dermal exposure to
treated diet, by consumption of maternal
feces, or by oral exposure to treated feed as
pups approach the age of weaning and begin
to consume solid food. These postnatal expo-
sures are difficult to quantify. Some of the
postnatal offspring exposures, even when
delivered via multiple mechanisms, may be
significantly lower than maternal exposures,
whereas others (e.g., milk plus treated feed
during late lactation) may be significantly
higher.
Numerous pharmacokinetic processes in
both the maternal animal and offspring
mentioned above (absorption, distribution,
placental and lactational transfer, protein
binding, metabolism, and excretion) deter-
mine the critical target-organ concentrations
of an active agent. These processes can vary
depending upon the delivered dose, route of
administration, duration of exposure, gesta-
tional stage, and species. Therefore, charac-
terization of exposure is a critical element in
defining the toxicologic dose–response (or
concentration–response) relationship for
proper interpretation and extrapolation of
study results. For example, placental transfer
of the antiepileptic drug phenytoin varies
signiﬁcantly among animal species as well as
with gestational age and route of administra-
tion (97). The gestational stage-dependent
kinetics of the herbicide 2,4,5-T in pregnant
mice would be expected to produce increas-
ing embryo or fetal exposures over the
course of pregnancy at the same maternally
administered dose (98). The dose-dependent
kinetics of the developmental neurotoxicants
phenytoin and valproic acid appear to be
accentuated in pregnant animals (99,100).
These findings indicate that maternally
administered dose may be a poor surrogate
for concentrations in the developing organ-
ism and emphasize the importance of expo-
sure monitoring in the evaluation of
developmental neurotoxicity. 
Exposure characterization is particularly
important in extrapolating study results to
humans. In some cases peak exposure is
linked to an adverse effect, and in other cases
the total exposure over time is linked to the
adverse effect; thus, different pharmacoki-
netic parameters may be important in pre-
dicting outcome, depending on the study
compound (101,102). For example, maximal
maternal plasma and embryo concentrations
(Cmax) correlate with the development of
neural tube defects in animals treated with
the neuroteratogen valproic acid (103).
Conversely, the AUC values for retinoids cor-
relate best with their teratogenic activity
(104,105). There is some evidence that peak
concentrations may play a crucial role in the
neurobehavioral effects of early lead exposure
in monkeys (106). For some developmental
toxicants such as 2-methoxyethanol, the criti-
cal pharmacokinetic parameter (e.g., Cmax
vs. AUC) apparently depends on the organ
system and developmental period during
which exposure occurs (107). These data sug-
gest that the pattern of exposure is a key
determinant of developmental toxicity, which
could have important implications for risk
assessment in humans (108,109).
The level of exposure characterization
may be limited by practical considerations in
a routine developmental neurotoxicity study
but ideally could at least include quantifica-
tion of the test compound (and any major
metabolites) in maternal plasma over time.
However, more proximate measures of off-
spring exposure may be essential for some
compounds. For example, lactational expo-
sure following administration of the same
maternal dose of methylmercury or inor-
ganic mercury to mice produced much
higher brain mercury concentrations in the
pups of dams given methylmercury despite
similar pup plasma mercury concentrations
in the two groups (110). Thus, plasma-level
data must be viewed in the context of the
disposition of a compound within the
organism, and all the pharmacokinetic
processes that determine the concentrations
of the active substance at the target must be
considered. Although such information is
most useful if analogous data are available
for humans, a lack of human data does not
preclude its use. For example, it can be
incorporated into physiologically based
models to improve the estimation of target
organ exposure in humans. The concept of
using PBPK models to better describe the
disposition of a xenobiotic in both rodents
and humans has been discussed in the con-
text of developmental risk assessment by
Welsch et al. (111) and is discussed in more
detail later in this article. 
Biochemical Markers of
Exposure and Effect in
Developing Animals
A biomarker of effect can be defined as a
measurable biochemical or physiologic alter-
ation within an organism recognized to have
a potential impact on health (112). A
biomarker of exposure may be a predictive
indicator that does not impact health.
Examination of biomarkers of effect follow-
ing exposure of a laboratory animal to a
neurotoxicant can be used to identify the
lowest dose capable of eliciting the potential
adverse effect and provide information on the
mechanism of action of the toxicant. A num-
ber of biomarkers have been used to identify
insult in the adult nervous system, including
astrocyte expression of glial fibrillary acidic
protein (GFAP), induction of stress proteins,
increased density of apoptotic cells, increased
neuronal degeneration, and alterations in
receptor density or function throughout the
brain (113,114) [for review, see Costa (115)].
The applicability of studies characterizing
biomarkers of effect in the developing ner-
vous system depends on a clear understanding
of the differences between juvenile and adult
brains and adequate documentation and vali-
dation studies. Therefore, the utility of the
methods and techniques used to identify spe-
ciﬁc biomarkers of effect in the adult brain to
evaluate the toxicity of compounds on the
nervous systems of developing animals
remains to be seen.
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Analysis of potential biomarkers of
exposure or effect in the developing nervous
system will be complicated by the rapid brain
growth and neuronal development that occur
during pre- and postnatal periods. Some of
the biomarkers of effect in adults may occur
normally in the developing brain as a result of
basic processes that underlie nervous system
growth and development. These processes—
including cell replication, migration, and dif-
ferentiation; apoptosis; myelination of
neurons; and synapse formation—occur in a
precisely ordered sequence in each region of
the brain, both in utero and postnatally, and
can be identified by molecular markers.
Exposure to a neurotoxicant may alter the
pattern of brain development, or the normal
pattern of development may be shifted in
time as a result of such exposure.
The biochemical and structural changes
that occur in the normal developing nervous
system are enormous. Markers of effect of low
speciﬁcity (e.g., brain weight determinations)
may be useful for evaluating toxicant actions
in the developing nervous system but are less
useful in evaluating toxicant actions in the
adult nervous system. For example, measures
of brain weight, protein or lipid concentra-
tion, and RNA or DNA content all produce
simple but accurate measures of brain devel-
opment and the schedule of that develop-
ment either in the whole brain or selected
regions. More dynamic measures include
incorporation of precursors into macromole-
cules such as proteins, lipids, RNA, or DNA,
indicating both amount and turnover in ner-
vous system tissue (116). Alterations in these
biochemical parameters may signal either a
change in pattern of brain development or a
shift in time of development. Distinguishing
between these two situations using biochemi-
cal measures can be a challenge. A description
of the normal or baseline pattern of ontologic
expression of the biochemical target through-
out development should be available before
any of the methods to evaluate biochemical
markers of effect described above are used for
routine analysis of developmental neurotoxi-
cant action. For example, an evaluation of
changes in protein or lipid content in a given
brain region will not be useful for assessing
developmental neurotoxicity until an analysis
of control brain protein or lipid content at
speciﬁc time points is available.
Assays to evaluate more specific bio-
chemical and pharmacologic markers of
exposure or effect can be conducted using
brain tissue homogenate preparations or his-
tologic sections. Examples of this approach
include measures of specific protein or
mRNA expression used as sentinels of appro-
priate brain development: myelin gene
expression and undernourishment (117);
muscarinic receptor expression and parathion
exposure (118); astroglial markers and
cocaine exposure (119); neurogranin and
myelin basic protein expression and exposure
to PCBs (120); and chemical-induced
hypothyroidism (121). Tissue homogenates
can be assayed to determine the levels of neu-
rotransmitters, receptor density, or receptor
afﬁnity in given regions of the brain. The func-
tion of these receptors may also be assessed by
analyzing the second messenger activity linked
to a given receptor type in tissue homogenates,
such as adenylate cyclase activity or ion flux
linked to receptor activation (122,123). Many
novel histologic methods have been developed
that allow detection and characterization of
alterations in specific regions of the brain.
Among the potentially useful methods for
identifying and localizing biochemical markers
of effect in the developing animal brain are sil-
ver stain for identiﬁcation of neuronal degen-
eration, and terminal deoxynucleotidyl
transferase-mediated deoxyuridine diphosphate
nick-end labeling for detection of apoptotic
cells. Immunohistochemical labeling of GFAP,
heat-shock proteins, and other developmen-
tally regulated proteins can also be assessed
(124). One must always be aware that the sen-
sitivity for many of these measures may be
much lower in the developing brain than in
the adult because of the dynamic and rapidly
changing events occurring in the normal devel-
opment of the nervous system. 
Microarray technologies offer a new
approach for examining alterations in gene
expression following chemical exposure (125).
This approach allows determination of the
presence or absence of particular nucleotide
sequences or the relative abundance of an
mRNA species in one sample compared with
another sample. The application of this tech-
nique most relevant to toxicity testing is in
determining the mRNA expression patterns of
numerous genes at a single time. Although it is
tempting to think of this procedure as one for
the high throughput of samples, this technol-
ogy instead provides a wealth of information
on a limited number of samples. From such
information, new hypotheses can be developed
and subsequently tested with more traditional
techniques such as reverse transcriptase-poly-
merase chain reaction. Given the vast number
of genes regulated during development, each
according to a distinct developmental temporal
pattern of expression, choosing any one of two
(or more) ages at which to examine chemical-
induced alterations in development is difﬁcult.
Measurements conducted at one developmen-
tal stage cannot distinguish between an
increase or decrease in a gene or simply a
change, delay, or acceleration in the normal
developmental proﬁle. Thus, the need to gen-
erate patterns of gene expression during the
course of development will require technologic
advancements before routine evaluation of
larger numbers of samples becomes feasible.
Even when these technical limitations are over-
come, changes in normal gene expression dur-





The precise characterization of dose–response
relationships and the extrapolation of results
from animals to humans are both issues of
paramount concern in toxicology and risk
assessment that may be improved by PBPK
modeling. A PBPK model is a series of math-
ematic equations based on organism-speciﬁc
and chemical-specific information that
describe the pharmacokinetic disposition of a
foreign chemical within an organism
(126,127). Solution of these equations will
simulate the concentration of a chemical (as
well as metabolites, if desired) with time in
the tissue of interest. The power of PBPK
modeling therefore lies in its ability to esti-
mate the amount of the active form of a
chemical at its target site within the body
over time, given virtually any exposure para-
digm. Moreover, extrapolation of an animal
PBPK model to humans can be attempted
through substitution with human physiologic
and, where feasible, human chemical-speciﬁc
information. Therefore, PBPK modeling can
improve our understanding of the risks of
developmental neurotoxicants by estimating
more precisely the exposure of the conceptus
or offspring to the active form of the toxicant
after maternal exposure. This approach also
improves our ability to extrapolate pharmaco-
kinetic data from animals to humans.
PBPK modeling of various chemicals in
animals during pregnancy has been reported
(95,128–132). For example, O’Flaherty et al.
(95) developed a PBPK model in the preg-
nant rat and mouse for 5,5´-dimethyloxazo-
lidine-2,4-dione (DMO) that accounted for
physiologic changes that occur throughout
gestation. Their model accurately simulated
DMO levels in embryo plasma and embryo
homogenate on gestational days 10, 11, and
13 after maternal exposure. More sophisti-
cated models could, in theory, simulate levels
of active toxicant within various tissues or
portions of tissues of the conceptus. Similarly,
modeling of lactational transfer in rats and
humans has been successful with certain
chemicals (133,134). Fisher et al. (134)
developed a PBPK model for lactating
women that estimated the amount of certain
volatile organic chemicals ingested by a nurs-
ing infant for a given nursing schedule after a
maternal occupational exposure. Important
features of the model included a milk com-
partment that changed in volume in response
to a nursing infant. 
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Pregnancy and lactation PBPK models
can design experiments, use information
related to mode of action, and identify
important data gaps. Under ideal circum-
stances, pharmacokinetic data obtained in
humans would be used to validate PBPK
models developed using animal data. Few
pharmacokinetic data are available for most
chemicals in pregnant or lactating women,
although there are exceptions for some
drugs,such as antiepileptic agents that must
often be administered throughout pregnancy
(135–137). Approaches currently used for
estimating human exposure have been
described (138).
The construction of a PBPK model begins
with the description of the body as a series of
compartments representing individual tissues
or tissue groups (Figure 2). Those tissues repre-
sented by compartments are selected for their
relevance to the disposition or action of the
chemical under consideration. For example, a
central nervous system (CNS) depressant
requires inclusion of the brain as a compart-
ment, whereas hepatic metabolism of a drug
necessitates the use of the liver as a compart-
ment. Similarly, a gestational PBPK model
requires compartments for the placenta and
the conceptus (95), whereas a lactational
model requires a milk compartment (134).
Following selection of appropriate compart-
ments, differential equations are written to
describe the fate of a chemical as it passes
through each tissue. Many examples of such
equations have been published. Organism-
speciﬁc parameters for which values must be
supplied to the differential equations include
tissue blood ﬂow, organ volume, cardiac out-
put, and in certain instances ventilation rate,
all of which can be obtained from the literature
(139). Chemical-speciﬁc parameters are, at a
minimum, elimination rate constants and tis-
sue:blood partition coefficients, and often
must be determined experimentally. Various
approaches have been used to determine these
values, and the speciﬁc methodology employed
depends to a large extent on the physio-
chemical and pharmacokinetic characteristics
of the chemical under study. If metabolite dis-
position is to be included in the model,
chemical-specific parameters for the parent
compound and the metabolites of interest
must be determined. Solution of the model
requires a computer equipped with software
that can solve simultaneous differential equa-
tions. Probably the most commonly used soft-
ware for this purpose has been Advanced
Continuous Systems Language (Pharsight
Corporation, Mountain View, CA, USA),
although many others can be used as well.
Although PBPK modeling is an extremely
powerful pharmacokinetic tool, it is not with-
out problems. Building PBPK models can
require considerable resources. At a minimum,
moderate programming skills are required,
and tissue:blood partition coefficients and
elimination rate constants can be difﬁcult and
time consuming to determine accurately for
many types of chemicals. Furthermore, with a
rodent gestational model, the limited amount
of tissue obtained from a conceptus or the pla-
centa requires the use of a large number of
animals. Although validation of animal PBPK
models can be accomplished by comparing
model predictions with empirical pharmacoki-
netic data, such data are often missing and
unobtainable in humans. An important chal-
lenge to modelers is to address these compli-
cating issues so that PBPK modeling can
become a more useful tool, routinely used in
all areas of toxicology. 
Practical Considerations 
in the Experimental Design 
of Pharmacokinetic Studies in
Developmental Neurotoxicity 
The selection of route of administration,
duration of exposure, and time during ner-
vous system development that the xenobiotic
will be administered can influence whether
developmental neurotoxicity occurs following
xenobiotic exposure. Thus, the decision of
when to initiate chemical exposure is critical.
Developmental toxicity studies are performed
typically by exposing pregnant animals to a
test substance beginning at uterine implanta-
tion and early stages of organogenesis, includ-
ing neurulation of the embryo (around
gestation day 6 in rats). Several studies have
identified specific malformations, especially
neural tube defects, that appear to have
resulted from preimplantation exposures
(140). Additionally, there is some indication
that very early gestational exposures to
cholinesterase-inhibiting chemicals, while
not causing such frank malformations as
neural tube defects, may produce more sub-
tle alterations in neurologic development
(141,142). Thus, maternal dosing beginning
at or before conception may be important for
testing some xenobiotics. Another reason for
initiating exposure before conception is that
some xenobiotics require long exposure times
to reach pseudo–steady-state conditions in
the dam (143).
Postnatal exposure of animals may be
critical in the design of developmental neuro-
toxicity studies and may depend upon the
experimental question. Postnatal brain devel-
opment occurs in both humans and rodents
(13,144). For example, a recent magnetic res-
onance imaging study in children age 3–15
identified evidence of quantifiable spatial
changes in the corpus callosum throughout
prepubertal childhood (145). Although
regional neurogenesis occurs predominantly
during gestation in both humans and rats,
neurogenesis of hippocampal dentate granule
cells and cerebellar neurons continues into
the postnatal period in rats compared to time
of parturation in humans (13). In each
species, the formation of the neural network
and connections as well as myelination are
significant processes that occur postnatally
[for review see Jacobson (146)]. Continuation
of dosing after birth may be necessary to
ensure exposure to some chemicals during
this critical period of brain development.
Direct neonatal dosing may be required for
developmental neurotoxicity testing of some
xenobiotics if lactational transfer does not
occur. Additional scenarios in which children
may be exposed (e.g., inhalation, chemical
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Figure 2. The conceptual framework for the PBPK model of gestational transfer of a chemical that is potentially
neurotoxic from the exposed mother to the fetus. Arrows connecting tissue compartments indicate movement of
chemical within the body. X denotes a time-dependent on-off switch. In this model, exposure may occur from intra-
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residues in food or water, pica) might be
addressed by direct neonatal dosing studies.
Although direct dosing of pups maximizes
neonatal exposure to the test compound, it is
not necessarily representative of chemical
exposure of the human fetus during the third
trimester, which depends on the metabolism
and pharmacokinetics of the chemical in the
mother. Practical considerations associated
with direct dosing of pups must be overcome.
Logistical problems associated with dosing
large numbers of pups in a study can be sig-
niﬁcant, and there are limitations in the vehi-
cle and volume of solution that can be
administered repeatedly to young animals
(147). One additional concern is that direct
oral dosing of very young pups might injure
or stress the pups, which could lead to func-
tional and behavioral effects not associated
with exposure to the test chemical. A poten-
tial advantage of direct dosing of a test chemi-
cal to pups at precisely known dose levels is
that this approach allows a more direct com-
parison of toxic response for adult and juve-
nile animals (148). In addition, if exposure is
limited to the postnatal period, direct dosing
of pups allows the use of interlitter dosing
designs that can significantly decrease the
number of animals required for any one
study. This information could be useful in
the assessment of age-related sensitivity to
xenobiotic exposure.
Another issue to be considered is the antic-
ipated route of human exposure. For food-use
pesticides with potential dietary residues, the
most appropriate administration route might
be oral (gavage or dietary). In some studies
dams are treated daily by gavage with a mea-
sured bolus dose of test substance that is dis-
solved or suspended in a nontoxic vehicle
[e.g., Dorman et al. (148)]. In a dietary study
the test substance is mixed into the feed,
which is made available to the animals for ad
libitum consumption throughout the dosing
period. Consumption of the mixed feed
occurs over a number of hours each day, but
consumption may be affected by unpalatabil-
ity of the admix. Dermal and inhalation
studies are conducted with limited daily expo-
sure periods of approximately 6 hr for the
dams. Similar problems can occur with expo-
sure via the drinking water. Both dietary and
drinking water routes of exposure require sub-
stantial evaluation to characterize chemical
stability in the dosing vehicle. Inhalation
developmental neurotoxicity studies can be
challenging because maternal separation from
pups may have a negative impact on the devel-
oping nervous system and there are difﬁculties
associated with exposing neonatal animals.
Some investigators have exposed dams and
neonatal pups simultaneously using bedding
and stainless steel caging held within a larger,
well-mixed exposure chamber (149–151). A
whole-body exposure system that permits the
simultaneous exposure of rat dams and neo-
natal pups has been developed recently and
used for developmental neurotoxicity studies
(152,153). In all cases, actual dose delivered to
the maternal animal depends on the absorp-
tion of the chemical, which may be affected
by many factors related to the physicochemi-
cal properties of the test substance or to the
study design. 
Fetal tissue (e.g., blood, brain) levels may
conﬁrm fetal exposure but may not be useful
in determining how to optimize exposure to
rat pups; there are few, if any, alternative
actions to increase in utero exposure levels. If
there is no placental transfer of the parent
compound or active metabolite in the rat, an
evaluation of differential metabolism may
indicate whether exposure of the human fetus
is likely, assuming that rat and human pla-
cental transfer are qualitatively similar. If the
assumption regarding relevance of rat placen-
tal transfer to humans is questioned, either a
different animal model (such as the mini pig)
might be appropriate, or it may be more rele-
vant to omit exposure during gestation and
focus on exposing rat pups after birth.
Rapid changes in organ development and
function occur during the neonatal period.
The low body weight of neonates compared
to adults and the high food consumption per
kilogram of body weight mean that tissue lev-
els of test chemicals can reach higher levels in
newborns than in adults. Furthermore, the
pharmacokinetics of many chemicals are age-
specific. For example, mercury, manganese,
and many other neurotoxic metals have
higher gastrointestinal absorption and less
effective renal or biliary excretion in neonates
than in adults (154,155). 
The metabolic capacity of the newborn
animal also differs from that observed in
adults. For example, postnatal animals may
be deficient in cytochrome P450 enzymes,
A-esterases, and carboxylesterase. The defi-
ciency in P450 enzyme activity could protect
the young animal from toxicants activated by
P450 because the activation potential is less
in the young animal than in the adult. This
may not be the case for organophosphorus
pesticide toxicity because both the activation
and detoxiﬁcation potential in young animals
usually is less than in adults (156), producing
increased toxicity in the young (157). This
increased toxicity stems mainly from an age-
related deficiency in detoxification enzymes
in the young (158–160).
The adult nervous system is protected
from many toxic substances circulating in
the blood by the BBB and blood–nerve bar-
riers. For this reason, there have been efforts
to deregulate possible neurotoxicants accord-
ing to their expected inability to enter the
nervous system (161). However, such
assumptions are problematic in attempts to
predict the potential neurotoxicity of a
chemical on the developing nervous system
at a time when the BBB may not be fully
functional. Even in adults, the BBB does not
always protect the brain from the passage of
toxicants because this barrier is permeable to
many xenobiotics. In addition, the BBB is in
a dynamic state, with altered permeability
occurring during physiologic and pathologic
conditions. Besides developmental and
pathophysiologic regulation of the BBB,
chemical transport into the various brain
regions can display regional differences. For
example, systemically administered gluta-
mate causes neurotoxicity in the circumven-
tricular organs and other areas of the CNS
that are least protected by the BBB (162). 
The timing of BBB development is a
matter of much controversy, partly because
the different markers used to deﬁne the bar-
rier appear at different times during develop-
ment (163,164). Furthermore, the timing of
BBB development varies among animal
species. For example, the BBB is not fully
developed during fetal life in rodents; how-
ever, complex tight junctions in endothelial
cells are present very early in human fetal
development (165). Species differences in
functional aspects of the BBB remain to be
determined. The BBB marker P-glycoprotein
also appears very early in brain endothelial
cells, indicating advanced differentiation even
at the earliest stages of development (166). In
contrast, astrocytic foot processes and the
basement membrane develop postnatally.
The relatively high permeability of fetal and
neonatal BBB has been ascribed to the uptake
of plasma solutes by endothelial cells through
a vesicular pathway (165). Although contro-
versial because of possible artifacts associated
with the use of high volumes of intravascular
tracers in developing animals, the BBB appar-
ently does not reach the stage of imperme-
ability seen in adults until some time
postnatally, thus increasing susceptibility to
blood-borne neurotoxicants (164,167–169).
The level of maturity of the BBB is not
the only factor that determines the transport
of neurotoxicants into the brain. The
physicochemical characteristics of blood-
borne compounds are also important deter-
minants in their capacity to cross the BBB.
Lipophilicity plays a major role in determin-
ing the rate at which xenobiotics may enter
the CNS compartment. Once inside the
CNS, a highly lipophilic substance tends to
accumulate because of the high lipid content
of myelin and other neural structures. Thus,
the extent of exposure of the CNS to a
lipophilic toxicant would be higher than the
systemic exposure of the organism (170). An
ionized compound will not enter the CNS as
readily as a compound that is not ionized, in
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which case it will enter the brain at a rate
proportional to its lipid:water partition coefﬁ-
cient (171). For example, methyl mercury
enters the brain much more readily than
inorganic mercury (110,172).
Besides lipophilic substances, other
substances that structurally resemble nutri-
ents normally taken up by the CNS can gain
facilitated or receptor-mediated access
through specific transport mechanisms
(173,174). Some of these mechanisms nor-
mally transport hormones, amino acids, pep-
tides, proteins, fatty acids, and trace
elements (175). One such transporter mech-
anism, the transferrin system, is present on
the surface of BBB endothelial cells. The
transferrin receptor complex transports iron
and manganese (176,177). Areas with high
levels of iron receive input from areas with
high levels of transferrin receptor in the vas-
culature and neuropil. For example, the
iron-rich areas of the substantia nigra and
globus pallidus receive input from the
nucleus accumbens and caudate putamen,
areas rich in transferrin receptors (178).
Transferrin and its receptor may also trans-
port other cations such as aluminum (179).
This mode of access of neurotoxic metals
into the CNS may also explain earlier obser-
vations of enhanced lead absorption during
iron deﬁciency and anemia (180).
Conclusions
Our goal was to review pharmacologic
factors that should be considered to improve
the design and interpretation of develop-
mental neurotoxicity studies. Many of the
pharmacokinetic methods, analytic chemical
techniques, and modeling approaches
needed to evaluate the pharmacokinetics of a
xenobiotic in the developing organism are
available to the research investigator. The
systematic application of these resources to
developmental neurotoxicology remains in
its infancy. Our intent was to emphasize the
value of collecting pharmacokinetic and
pharmacodynamic data in developmental
neurotoxicity studies to improve the risk
assessment of xenobiotics. Our hope is that
this information will inform and stimulate
the reader to consider the following ques-
tions when designing studies to evaluate
potential developmental neurotoxicity of a
xenobiotic:
• Will the exposure to the test chemical
in utero and postnatally be confirmed or
characterized adequately?
• Are the appropriate critical periods of
nervous system development considered
in the study design?
• Are the route and duration of exposure
appropriate to detect developmental neuro-
toxicity in laboratory animals relevant to
humans?
• Was the experiment designed so as to
evaluate direct actions of the chemical sep-
arately from developmental neurotoxicity?
• Are there data to suggest that species or
life-stage differences in xenobiotic phar-
macokinetics or biologic response may
occur in developing animals following
exposure?
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